Page 32 - Johnson Amp News Today

The pivotal ADVENT trial of the Farapulse pulsed field ablation (PFA) system developed by Boston Scientific Corp. returned positive results at one year, according to a presentation at the ESC Congress 2023 that was simultaneously published in the New England Journal of Medicine. The study compared Farapulse, a nonthermal treatment that ablates heart tissue, to radiofrequency or cryoablation, the current standards of care for paroxysmal atrial fibrillation.

Johnson & Johnson stock (NYSE: JNJ) has seen a 3% fall in a month, compared to a 2% fall for the broader S&P500 index.

Judge Thomas Rose of the U.S. District Court for the Southern District of Ohio withdrew from a case that could block Medicare's drug price negotiation program.

CNBC's Jim Cramer explained how to get children involved with investing in an age-appropriate way.

Stocks are poised to open slightly higher Wednesday, while Citigroup maintains a buy rating on Club name Apple (AAPL) ahead of its Sept. 12 product event.

Johnson & Johnson updated on Wednesday its 2023 financial guidance in the wake of the Kenvue Inc. separation that was completed last week. The drug maker now...

Johnson & Johnson maintains its quarterly dividend of $1.19 a share after spinning out consumer-health company Kenvue, although it lowers its earnings and...

Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives. 

Lilly's Jardiance is among the first 10 prescription drugs subject a new, contentious negotiation process between Medicare and drugmakers.

Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications...